Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06927739 · ClinicalTrials.gov registry record · Phase 2
Focused Orticumab Research for Treating Inflammation in Coronary Arteries
A Phase 2 study of Inflammation and Heart Disease, sponsored by Abcentra.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
- 20
- Study locations
NCT06927739: Recruiting Phase 2 study of Inflammation and Heart Disease, sponsored by Abcentra.
NCT06927739 is a Phase 2 study of Inflammation and Heart Disease that is actively recruiting participants, run by Abcentra. The registered enrollment target is 240 participants, below the 286-participant average among 132 other Inflammation trials with a reported enrollment target (16% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06927739, a Phase 2 study of Inflammation and Heart Disease, is actively recruiting participants, sponsored by Abcentra.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical trial is to determine the clinical effect of orticumab treatment on inflammation in study participants with prior myocardial infarction who have elevated coronary inflammation based on CCTA. The main question it aims to answer is: Clinical effects of orticumab treatment on inflammation of the coronary artery parameters measured with CCTA Researchers will compare the effects with placebo group after 6 months of treatment Participants will Keep the planned study visit appointments Provide complete information about medical and medical history Speak to the study doctor before changing any of non-study treatments, including starting new medications, receiving any vaccinations, or setting out to join any other clinical studies
Primary Outcome
Analysis of the mean FAI score around the coronary arteries will be performed from baseline and 6-month Coronary Computed Tomography Angiography (CCTA) procedures. FAI-score is a standardized measurement of coronary inflammation for each coronary artery (adjusted for age, sex as well as technical, biological, and anatomical characteristics) to allow individualized interpretation of the degree of coronary inflammation. FAI-Score is given at a scale of 0-100 with arbitrary unit. A higher FAI-sco
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Orticumab
Study Locations (20)
Central Hungary
- Abcentra Investigational Site - Budapest
- Abcentra Investigational Site - Budapest
- Abcentra Investigational Site - Budapest
California
- Abcentra Investigational Site - Los Angeles
- Abcentra Investigational Site - Torrance
Florida
- Abcentra Investigational Site - Boca Raton
Indiana
- Abcentra Investigational Site - Richmond
Kentucky
- Abcentra Investigational Site - Louisville
Maryland
- Abcentra Investigational Site - Baltimore
Michigan
- Abcentra Investigational Site - Midland
Moravian-Silesian Region
- Abcentra Investigational Site - Ostrava
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2025-08-11 |
| Est. Completion | 2027-06-01 |
| Phase | Phase 2 |
What NCT06927739 shows while recruiting
NCT06927739 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 286-participant average among 132 other Inflammation trials with a reported enrollment target (16% lower).
The record links to 6 conditions, with Inflammation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06927739 names 20 study sites across 17 states, led by Central Hungary, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06927739 about?
NCT06927739 is a clinical study titled "Focused Orticumab Research for Treating Inflammation in Coronary Arteries". The goal of this clinical trial is to determine the clinical effect of orticumab treatment on inflammation in study participants with prior myocardial infarction who have elevated coronary inflammation based on CCTA. The main question it aims to answer is: Clinical effects of orticumab treatment on...
What is the current status of trial NCT06927739?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2025-08-11. Estimated completion is 2027-06-01.
What conditions does trial NCT06927739 study?
This clinical trial studies the following conditions: Inflammation, Heart Disease, Coronary Arterial Disease (CAD), Acute Coronary Syndromes, Myocardial Infarct.
What interventions are being tested in trial NCT06927739?
The interventions under investigation include: Placebo (DRUG), Orticumab (DRUG).
Who is sponsoring clinical trial NCT06927739?
This trial is sponsored by Abcentra, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06927739 being conducted?
This trial has 20 study locations across California, Florida, Indiana, Kentucky, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06927739's enrollment target sits among peer trials
240 24th of 132 higher than 108 of 132 other Inflammation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Inflammation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reducing Frailty for Older Cancer Survivors Using Supplements II
RECRUITING · Phase 2
-
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
RECRUITING · Phase 2
-
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
RECRUITING · Phase 2
-
Modulating Exercise Dosage to Improve Concussion Recovery
RECRUITING · Phase 2
-
Passive Stretching in Peripheral Arterial Disease Patients
RECRUITING · Phase 2
-
Clinical Trial of the Seaweed Supplement Fucoidan in Survivors of Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI